HB 5255 – Rhode Island

Status: In Process
Year Introduced: 2023
Link: http://webserver.rilegislature.gov/BillText/BillText23/HouseText23/H5255.pdf

This act would establish a prohibition on health care insurers from requiring or conducting a review for prescription medicine that is used in the treatment of alcohol or opioid use disorder, that contains Methadone, Burenorphine, or Naltrexone or that was approved for the mitigation of opioid withdrawal symptoms.

Return to Database Search

© 2018- The SLIHCQ DatabaseInitial funding for this project was provided by the Robert Wood Johnson Foundation. The views expressed here do not necessarily reflect the views of the Foundation.

Associated Litigation:

No items found